CART 891
Alternative Names: CART-891Latest Information Update: 28 Jun 2022
At a glance
- Originator Multitude Therapeutics
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Clinical Phase Unknown Multiple myeloma
Most Recent Events
- 17 Jun 2022 CART 891 is available for licensing as of 17 Jun 2022. https://www.multitudetherapeutics.info/partnering
- 17 Jun 2022 Clinical trials in Multiple myeloma in USA (Parenteral) (Multitude Therapeutics pipeline, June 2022)
- 17 Jun 2022 Multitude Therapeutics plans to submit an IND for Multiple myeloma (Multitude Therapeutics pipeline, June 2022)